Showing 2151-2160 of 5697 results for "".
- RetinAI and FVS Announce CE-MDR Certification for Co-Developed AI-Based DR Screening Algorithm, LuxIAhttps://modernod.com/news/retinai-and-fvs-announce-ce-mdr-certification-for-co-developed-ai-based-dr-screening-algorithm-luxia/2482773/RetinAI US and Fundación Ver Salud (FVS) have jointly announced that LuxIA, their co-developed AI algorithm for diabetic retinopathy (DR) screening, has successfully received CE-MDR certification as a Class IIb medical device under the European
- SpyGlass Pharma Presents 18-Month Data Demonstrating Improvements in Visual Acuity with IOL-Mounted Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-presents-18-month-data-demonstrating-improvements-in-visual-acuity-with-iol-mounted-drug-delivery-platform/2482772/SpyGlass Pharma announced that 18-month data from the first-in-human study of the SpyGlass Drug Delivery Platform demonstrated improvements in both visual acuity and IOP outcomes, key objectives for long-term treatment of glaucoma or ocular hypertension. Th
- Azalea Vision Raises €9 Million to Further Develop Intelligent Connected Vision Platformhttps://modernod.com/news/azalea-vision-raises-eur9-million-to-further-develop-intelligent-connected-vision-platform/2482765/Startup biotech company Azalea Vision announced the first closing of its €15 million Series A funding round, raising €9 million. In addition, the company announced that Robert J. Dempsey has been appointed Chairman of the Board to guide strategic growth in the European an
- Nordic Pharma Presents Data and Patient Experience Study for Lacrifill Canalicular Gel at ASCRShttps://modernod.com/news/nordic-pharma-presents-data-and-patient-experience-study-for-lacrifill-canalicular-gel-at-ascrs/2482756/Nordic Pharma will be presenting recently published patient data and patient experience study for Lacrifill Canalicular Gel, a novel therapy for dry eye symptoms, during the ASCRS annual meeting in Los Angeles. The April issue of Ca
- Nordic Pharma Receieves CE Mark Approval for Lacrifill Canalicular Gelhttps://modernod.com/news/nordic-pharma-receieves-ce-mark-approval-for-lacrifill-canalicular-gel/2482729/Nordic Group, the parent company of Nordic Pharma, announced that its dry eye therapy Lacrifill has received CE mark approval. This regulatory milestone, which Nordic says was achieved several months ahead of schedule, allows Nordic Pharma to introduce Lacrifill across Europea
- Pantheon Vision Announces Partnership with EyeDeal Medical to Develop Bioengineered Corneal Implanthttps://modernod.com/news/pantheon-vision-announces-partnership-with-eyedeal-medical-to-develop-bioengineered-corneal-implant/2482719/Pantheon Vision today announced a partnership with manufacturer EyeDeal Medical to develop an artificial, bioengineered corneal implant. Their goal, the company states, is to eliminate corneal blindness by removing the need for human donor corneal tissue. Corneal blindness is the
- Harrow Secures 5-Year Strategic Agreement for Triesence and Announces Next-Generation Developmenthttps://modernod.com/news/harrow-secures-5-year-strategic-agreement-for-triesence-and-announces-next-generation-development/2482696/Harrow announced the execution of a 5-year strategic supply and development (SSD) agreement for Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL. This preservative-free synthetic corticosteroid is FDA-approved for visualization during vitrectomy
- Nicox Announces New Data from the NCX 470 Mont Blanc Trial, Provides Development Updateshttps://modernod.com/news/nicox-announces-new-data-from-the-ncx-470-mont-blanc-trial-provides-development-updates/2482684/Nicox, an international ophthalmology company, shared new data on their intraocular pressure (IOP)-lowering medication NCX 470 at the 2025 American Glaucoma Society (AGS) Annual Meeting this past weekend. The French company also shared developmental updates from the 470 Mont Blanc phase 3 clinica
- Call for Nominations: Prevent Blindness Seeks to Honor Leaders in Vision Healthhttps://modernod.com/news/call-for-nominations-prevent-blindness-seeks-to-honor-leaders-in-vision-health/2482661/Prevent Blindness, one of the nation’s largest eye health and safety nonprofit organizations, issued their call for nominations for the “
- Lumenis Launches OptiLIFT, Device to Address Lower Lid Laxity and Impaired Blinkinghttps://modernod.com/news/lumenis-launces-optilift-device-to-address-lower-lid-laxity-and-impaired-blinking/2482652/Lumenis announced the launch of OptiLIFT, a new device that uses Dynamic Muscle Stimulation technology (DMSt) to tone facial muscles to improve lower lid laxity and impaired blinking. OptiLIFT marks one of the first treatment options that eliminates the need for surgery. “Op